Lineage Cell Therapeutics (LCTX) EPS (Basic) (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly EPS (Basic) of -$0.02 for Q1 2026, up 34.81% year-over-year from -$0.01 in Q1 2025, and up 34.09% quarter-over-quarter from -$0.03 in Q4 2025.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) EPS (Basic) (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' EPS (Basic) history runs 17 years deep, the most recent figure standing at -$0.02 for Q1 2026.
- In Q1 2026, EPS (Basic) rose 34.81% year-over-year to -$0.02; the TTM figure through Mar 2026 stood at -$0.22 (down 159.86% YoY), while the FY2025 annual figure was -$0.28, down 196.67% from the prior year.
- EPS (Basic) for Q1 2026 stood at -$0.02, up from -$0.03 in the prior quarter.
- The five-year high for EPS (Basic) was -$0.02 in Q3 2024, with the low at -$41.81 in Q1 2022.
- The 5-year median for EPS (Basic) is -$0.03 (2024), against an average of -$2.49.
- Peak annual rise in EPS (Basic) reached 99.98% in 2022, while the deepest fall reached 458211.28% in 2022.
- Lineage Cell Therapeutics' EPS (Basic) stood at -$0.04 in 2022, then climbed by 26.66% to -$0.03 in 2023, then jumped by 40.54% to -$0.02 in 2024, then plunged by 83.55% to -$0.03 in 2025, then surged by 34.09% to -$0.02 in 2026.
- Business Quant data shows LCTX's EPS (Basic) at -$0.02 in Q1 2026, -$0.03 in Q4 2025, and -$0.08 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -3.06 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.18 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.06 |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | -0.03 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.03 |
| Mar 31, 2026 | -0.02 |
| Dec 31, 2025 | -0.03 |
| Sep 30, 2025 | -0.01 |
| Jun 30, 2025 | -0.08 |
| Mar 31, 2025 | -0.03 |
| Dec 31, 2024 | -0.02 |
| Sep 30, 2024 | -0.02 |
| Jun 30, 2024 | -0.03 |
| Mar 31, 2024 | -0.04 |
| Dec 31, 2023 | -0.03 |
| Sep 30, 2023 | -0.04 |
| Jun 30, 2023 | -0.03 |
| Mar 31, 2023 | -0.03 |
| Dec 31, 2022 | -0.04 |
| Sep 30, 2022 | -0.04 |
| Jun 30, 2022 | -0.04 |
| Mar 31, 2022 | -0.04 |
| Dec 31, 2021 | -0.17 |
| Sep 30, 2021 | -0.05 |